Wegovy’s cardiovascular benefit: who SELECT studied and what changed

Wegovy is FDA-approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either overweight or obesity, in combination with diet and physical activity changes specified in its label. In SELECT, which tested injected semaglutide in people without diabetes, the primary event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months.¹²

The study starts with established disease

SELECT enrolled 17,604 adults with preexisting cardiovascular disease and overweight or obesity who did not have diabetes. This is a secondary-prevention question. Someone with high cholesterol or another risk factor alone is not automatically in the same population as someone with a documented cardiovascular diagnosis. The trial also does not answer what to expect in every group not represented in its enrollment criteria.²

The current label names the cardiovascular indication for both Wegovy injection and tablets. FDA’s March 2024 announcement was for the injection. SELECT did not randomize people between tablets and injections. Use the current product label to check the indication and the original trial to identify which formulation and population produced the event numbers quoted here.¹²³

Read the event rate and the hazard ratio together

The primary endpoint combined cardiovascular death, nonfatal heart attack and nonfatal stroke. The observed rates of 6.5% versus 8.0% differ by 1.5 percentage points. The reported hazard ratio was 0.80. The commonly quoted 20% reduction refers to the relative difference in event hazard in the study. It does not mean that 20 people out of every 100 avoided an event, and the composite does not assign the same effect to each component.²

Why trial enrollment and product labeling both matter

A study enrollment criterion tells you how researchers selected participants. An FDA indication tells you what a particular product is approved to address. SELECT studied participants without diabetes, whereas the cardiovascular indication in the current Wegovy label is framed around established cardiovascular disease and overweight or obesity. Compare both records rather than importing every trial criterion into the label or assuming the trial’s event rates apply to everyone the label covers. A clinician can distinguish the purpose of a proposed prescription from the characteristics of the population behind the quoted event percentages.¹²

Keep other heart outcomes in their own records

A study of breathlessness, physical limitation or walking ability in heart failure answers a different question from SELECT’s major-event endpoint. See the heart failure trial guide for that evidence. A report about weight change likewise cannot stand in for a cardiovascular event study.²

At a medical weight management consultation, bring the cardiovascular diagnosis record and the list of clinicians already involved in your care. Ask which outcome is the goal and which clinician will reconcile the product label, health history and existing cardiovascular plan. The group average helps explain the indication. Your own circumstances require that separate clinical review.